UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 2, 2008 (December 27, 2007)

 

ALLOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

000-29815

54-1655029

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

 

 

 

11080 CirclePoint Road, Suite 200

 

Westminster, Colorado

80020

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (303) 426-6262

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01                Other Events.

 

                On December 27, 2007, Allos Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that an independent Data Monitoring Committee (DMC) completed the pre-specified 65-patient safety review of data from the Company’s pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial continue per the protocol.  The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01                Financial Statements and Exhibits.

 

(d)            Exhibits

 

99.1

 

Press Release, dated December 27, 2007, entitled “ Interim Safety Analysis Supports Continuation of Allos Therapeutics’ Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma .”

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:     January 2, 2008

 

 

 

 

ALLOS THERAPEUTICS, INC.

 

 

 

 

 

 

 

By:

/s/ David C. Clark

 

 

David C. Clark

 

Its:

Vice President, Finance and Treasurer

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release, dated December 27, 2007, entitled “ Interim Safety Analysis Supports Continuation of Allos Therapeutics’ Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma .”

 

4

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024 Click aqui para mais gráficos Allos Therapeutics, Inc. (MM).
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024 Click aqui para mais gráficos Allos Therapeutics, Inc. (MM).